302 related articles for article (PubMed ID: 17310380)
41. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
Wu J; Fu J; Zhang M; Liu D
J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
[TBL] [Abstract][Full Text] [Related]
42. Increased interleukin-10 production by ASC-deficient CD4+ T cells impairs bystander T-cell proliferation.
Narayan S; Kolly L; So A; Busso N
Immunology; 2011 Sep; 134(1):33-40. PubMed ID: 21718313
[TBL] [Abstract][Full Text] [Related]
43. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
44. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
45. Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells.
Spies CM; Gaber T; Hahne M; Naumann L; Tripmacher R; Schellmann S; Stahn C; Burmester GR; Radbruch A; Buttgereit F
Immunol Lett; 2010 Jun; 131(1):24-32. PubMed ID: 20363256
[TBL] [Abstract][Full Text] [Related]
46. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy.
Zimmerman Z; Maniar T; Nagorsen D
Int Immunol; 2015 Jan; 27(1):31-7. PubMed ID: 25239133
[TBL] [Abstract][Full Text] [Related]
47. Glucocorticoids inhibit CD40 ligand expression of peripheral CD4+ lymphocytes.
Bischof F; Melms A
Cell Immunol; 1998 Jul; 187(1):38-44. PubMed ID: 9682002
[TBL] [Abstract][Full Text] [Related]
48. Acquisition of interleukin-5 secretion by human naive T-helper cells is regulated by distinct signals from both the T-cell receptor/CD3 complex and CD2.
Semnani RT; Svoboda K; Khoshnood B; van Seventer GA
Scand J Immunol; 1998 May; 47(5):436-43. PubMed ID: 9627127
[TBL] [Abstract][Full Text] [Related]
49. Glucocorticoids drive human CD8(+) T cell differentiation towards a phenotype with high IL-10 and reduced IL-4, IL-5 and IL-13 production.
Richards DF; Fernandez M; Caulfield J; Hawrylowicz CM
Eur J Immunol; 2000 Aug; 30(8):2344-54. PubMed ID: 10940925
[TBL] [Abstract][Full Text] [Related]
50. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation and interleukin-2 secretion by physiologic combinations of dexamethasone and prostaglandin E2.
Elliott L; Brooks W; Roszman T
Cell Mol Neurobiol; 1993 Dec; 13(6):579-92. PubMed ID: 7910781
[TBL] [Abstract][Full Text] [Related]
52. Selective effects of Lactobacillus casei Shirota on T cell activation, natural killer cell activity and cytokine production.
Dong H; Rowland I; Tuohy KM; Thomas LV; Yaqoob P
Clin Exp Immunol; 2010 Aug; 161(2):378-88. PubMed ID: 20456417
[TBL] [Abstract][Full Text] [Related]
53. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation.
de Waal Malefyt R; Yssel H; de Vries JE
J Immunol; 1993 Jun; 150(11):4754-65. PubMed ID: 7684412
[TBL] [Abstract][Full Text] [Related]
54. Synergistic inhibitory activities of interleukin-10 and dexamethasone on human CD4+ T cells.
Brunetti M; Mascetra N; Martelli N; Ranelletti FO; Musiani P; Aiello FB
Transplantation; 2002 Oct; 74(8):1152-8. PubMed ID: 12438963
[TBL] [Abstract][Full Text] [Related]
55. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
[TBL] [Abstract][Full Text] [Related]
56. Differential effects of CD4 and CD8 engagement on the development of cytokine profiles of murine CD4+ and CD8+ T lymphocytes.
Campbell SB; Komata T; Kelso A
Immunology; 2000 Mar; 99(3):394-401. PubMed ID: 10712669
[TBL] [Abstract][Full Text] [Related]
57. Costimulation by purified intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 induces distinct proliferation, cytokine and cell surface antigen profiles in human "naive" and "memory" CD4+ T cells.
Semnani RT; Nutman TB; Hochman P; Shaw S; van Seventer GA
J Exp Med; 1994 Dec; 180(6):2125-35. PubMed ID: 7525848
[TBL] [Abstract][Full Text] [Related]
58. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
Moore PA; Zhang W; Rainey GJ; Burke S; Li H; Huang L; Gorlatov S; Veri MC; Aggarwal S; Yang Y; Shah K; Jin L; Zhang S; He L; Zhang T; Ciccarone V; Koenig S; Bonvini E; Johnson S
Blood; 2011 Apr; 117(17):4542-51. PubMed ID: 21300981
[TBL] [Abstract][Full Text] [Related]
59. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
60. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
